文献

重组抗人HLA-ABC单克隆抗体(克隆号W6/32) ，小鼠IgG2a Kappa（Recombinant Anti-human HLA-ABC Monoclonal Antibody (Clone: W6/32), Mouse IgG2a Kappa，货号：PA007472.m2a Syd Labs）

人类主要组织相容性复合体I类抗原（HLA-A, HLA-B, HLA-C）是表达于绝大多数有核细胞表面的单跨膜异二聚体糖蛋白，由重链与β2-微球蛋白（β2m）共同组成，在内源性抗原递呈及CD8+ T细胞和NK细胞的免疫监视中发挥核心作用。经典克隆号W6/32单克隆抗体能够特异性识别构象完整的HLA-A、HLA-B和HLA-C三元复合物表位，是免疫学研究中最经典且广泛应用的构象依赖性单抗之一。抗人HLA-ABC单抗（W6/32抗体）被广泛应用于多色流式细胞术检测细胞表面HLA Class I表达水平、免疫沉淀（IP）分析MHC-I复合物相互作用、阻断NK细胞及T细胞识别实验，以及评估肿瘤免疫逃逸与移植排斥反应机制。

Syd Labs推出的重组抗人HLA-ABC单抗（W6/32抗体）采用先进的哺乳动物表达系统重组合成，克服了传统杂交瘤来源试剂的批间差异，确保极高的特异性与纯度。该产品按体内实验级（In Vivo Grade）标准严格精制，具备极低内毒素（Low Endotoxin）水平且无防腐剂成分。特别引入的Human IgG1 Fc Silent工程化结构，通过重链恒定区的精准突变完全排除了与细胞表面Fcγ受体的非特异性结合，消除了假阳性背景及非特异性细胞激活。在复杂的免疫细胞功能阻断、体外细胞培养及体内模型研究中，Syd Labs 9.3F10与W6/32等重组抗体系列能够为科研人员提供科学严谨、高重复性的实验支持。

抗人HLA-ABC单抗(W6/32)部分参考文献:

1. Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing
Kaur, A., et al. J Immunol. 2023. doi: 10.4049/jimmunol.2300405
“This study uses mass spectrometry to explore tapasin-mediated tryptophan editing in HLA-B44 peptidomes. The W6/32 antibody (anti-human HLA-ABC) was purified from mouse ascites and crosslinked to PureProteome Protein A magnetic beads for immunoaffinity purification. Cells were stained with W6/32-FITC antibody for surface HLA class I analysis via quantitative flow cytometry, revealing a significant reduction in HLA-B44:05 molecules on tapasin knockout cells compared to wild-type cells. A slight, non-significant decrease in HLA-B44:05 surface stability was observed in tapasin knockout cells in the presence of brefeldin A.”

2. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins
Zhang, F., et al. Proc Natl Acad Sci U S A. 2022. doi: 10.1073/pnas.2208191119
“This study investigates how sarbecovirus ORF7a proteins inhibit MHC-I antigen presentation. Human 293T, HuH7.5, U2OS, and A549/ACE2 cells were transduced with lentiviral vectors expressing SARS-CoV-2 ORF7a or Nef and stained with the pan-HLA-ABC antibody W6/32 for flow cytometry. MHC-I surface levels, measured by median fluorescence intensity, were reduced in ORF7a-expressing cells. The study compared wild-type and ORF7-deleted SARS-CoV-2 strains, confirming ORF7a’s role in suppressing MHC-I expression.”

3. Assessments of HLA-I Specificities of Anti-HLA-I Monoclonal Antibodies Using Solid Phase Bead Arrays
Zaitouna, A. J., et al. Bio Protoc. 2020. doi: 10.21769/BioProtoc.3862
“This study evaluates anti-HLA-I monoclonal antibody specificities using solid phase bead arrays. The W6/32 antibody, a pan anti-HLA class I antibody, was used to normalize HLA-I protein levels on Labscreen and FlowPRA Single Antigen Beads. Biotinylated W6/32 was tested at various dilutions (undiluted to 1:100) alongside anti-Bw4 and anti-Bw6 antibodies. Representative data showed W6/32 binding to HLA-I beads, with isotype control IgG2a used for comparison.”

4. Strategies for the measurements of expression levels and half-lives of HLA class I allotypes
Raghavan, M., et al. Hum Immunol. 2019. doi: 10.1016/j.humimm.2019.01.011
“This study describes methods for measuring HLA class I expression and half-lives using the W6/32 antibody (anti-human HLA-ABC). Flow cytometry histograms showed W6/32 signals for monocytes, NK cells, B cells, CD8+ T cells, and CD4+ T cells, with geometric mean values quantifying HLA class I expression. The W6/32 antibody was chosen for its broad recognition of most HLA class I allotypes, facilitating consistent assessment across healthy donors.”

5. Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
Akazawa, Y., et al. Cancer Sci. 2019. doi: 10.1111/cas.14022
“This study examines HLA class I expression in early-stage hepatocellular carcinoma (HCC) using the W6/32 antibody (anti-human HLA-ABC). Flow cytometry analysis of tissue from five HCC patients compared HLA class I expression between cancer cells and non-tumorous hepatocytes. The mean fluorescence intensity ratio of W6/32 staining indicated higher HLA class I expression in cancer cells, enhancing sensitivity to cytotoxic T lymphocytes. Heterogeneous expression was observed in non-tumorous hepatocytes in one case.”